Program
rilogrotug
Also written as “AV-380” and “Rilogrotug”.
Its studies are mostly in Cachexia, led by LG Chem.
Furthest: phase 3, since Oct 15, 20263 company-led studies, 1 open or runningNext primary completion: Mar 2030 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| LG Chem | 31 open or running | phase 3since Oct 15, 2026 | Mar 8, 2021 | Mar 2030phase 3 · NCT07888075 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 8, 2021First study: phase 1 study in CachexiaFirst studyNCT04815551 · 51 enrolled · United States
- May 2, 2023Phase 1 study in CachexiaNCT05865535 · 24 enrolled · United States
- Oct 15, 2026Phase 3 study in CachexiaPhase 3 reachedNCT07888075 · 950 planned
- Oct 28, 2026Primary completion moved from 2028-10 to 2030-03Date moved laterphase 3 · +17 months · NCT07888075
Ahead
- Mar 2030Primary completion: phase 3 study in CachexiaNCT07888075
TargetBeta
“A humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against human growth/differentiation factor 15 (GDF-15; macrophage inhibitory cytokine-1; MIC-1; non-steroidal anti-inflammatory drug-inducible gene-1; NAG-1; placental transforming growth factor-beta; pTGFB; prostate-derived factor; ”NCIt, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| visugromabrule | catalym-gmbh | phase 3 | 6 |
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07888075Cachexia | 3 | Not yet recruiting | Mar 2030 | 950 |
| NCT05865535Cachexia · United States | 1 | Completed | Aug 11, 2026 | 24 |
| NCT04815551Cachexia · United States | 1 | Completed | Jan 14, 2022 | 51 |
How it is read
Names in the registry
- “AV-380”, 2 entries
- “Rilogrotug”, 1 entry
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.